January 1, 2019Theranostics118 citationsOpen Access

Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles

MSMinati Satpathy LWLi‐Ya Wang RZRafał Zieliński

Key Points

Key points are not available for this paper at this time.

Abstract

The inability to completely excise peritoneal metastatic tumors by debulking surgery as well as resistance to chemotherapy are the major clinical challenges for ovarian cancer treatment. This targeted cancer therapy has the potential for the development of effective treatment for metastatic ovarian cancer.

问 AI

Bookmark

View Full Paper

Cite This Study

Satpathy et al. (Tue,) studied this question.

synapsesocial.com/papers/6a3222622acd7f61e3cc1d1f https://doi.org/https://doi.org/10.7150/thno.29964

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer1994 · 66 citations
2The resurgence of platinum-based cancer chemotherapy2007 · 4,715 citations
3Treatment of HER2-Positive Metastatic Breast Cancer2015 · 17 citations
4Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging2016 · 323 citations
5Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer2013 · 325 citations

问 AI

Bookmark

View Full Paper